Transplantation-associated thrombotic microangiopathy (TA-TMA) is a severe complication which affects 5-74% of patients undergoing allogeneic HSCT. 1 Risk factors for TA-TMA include the use of high doses of radio-and chemotherapy, infections, GVHD, and the use of cyclosporine (CsA) or tacrolimus. 1, 2 There is no consensus on the most appropriate treatment for patients with TA-TMA. The role of plasma exchange (PE) is controversial 3 since response rates are considerably lower than in patients with thrombotic thrombocytopenic purpura (TTP). Thus, many patients require additional therapeutic strategies such as protein A immunoadsorption, splenectomy, nitric oxide, defibrotide, and immunosuppressive agents such as vincristine or steroids. [4] [5] [6] We have treated seven allograft recipients developing TA-TMA from 2002 to 2004. Patient characteristics are shown in Table 1 . TA-TMA occurred at a median of 61 days (25-276). Diagnosis was based on the presence of anemia and thrombocytopenia (median 30 Â 10 9 /l; range 6-50), increased LDH (median 1424 U/l; range 955-2127), and schistocytosis. Renal impairment occurred in one patient and neurological disturbances in three patients. Treatment plan consisted of switch from CsA to tacrolimus maintaining blood levels at the lower end of the therapeutic range (5 ng/ml), with PE and/or vincristine being added for the lack of response.
Four of seven patients were classified as grades 3-4 according to the grading system reported by Zeigler et al., 7 and three patients as grade 2. All patients classified as grades 3-4 received daily PE, except for one who was hemodynamically unstable and received vincristine alone. In the absence of response to PE, vincristine was added to the treatment. Patients classified as grade 2 TA-TMA received only vincristine, which was administered at a dose of 1 mg once daily i.v. (patients younger than 6 and 9 years received 0.6 and 0.7 mg, respectively) on days 1, 4, 8, and also on day 11 when they had not responded after three doses (only one patient received two doses due to a drop in WBC counts).
Overall, six out of the seven patients responded and only one of them died due to TA-TMA-related complications. The remaining six patients reached complete response at a median of 11 days (range: 7-90 days) with platelet counts 4100 000/mm 3 and hemoglobin levels 410 g/dl. Among responding patients, clinical response was observed within 11 days of treatment although, in two patients, biological parameters improved after 70 days. During treatment with vincristine, WBC counts decreased in four patients but all recovered normal values within 2 weeks and only one patient did not receive the planned dose due to toxicity. After 565 days (170-1060 days), all the responding patients were alive and in complete response. No TA-TMA recurrence was observed.
Only two studies have reported on the combined use of PE and vincristine in the treatment of post transplant TA-TMA.
1,5 Silva et al. 5 described one response out of eight patients diagnosed with TA-TMA, while Daly et al. described four patients treated with vincristine among 25 TA-TMA patients. Mortality rate reached 96% in this latter study for the whole series of patients.
Pathogenesis of TA-TMA within the allogeneic transplant setting has been attributed to the endothelial cells damage induced by radiotherapy, chemotherapy, infections, or GvHD. 3 This endothelial damage favours the release of tissue factor into the circulation and the formation of platelet thrombi. 8 PE is useful in TTP because it removes autoantibodies against ADAMTS-13, UlvWF multimers, which are related with the development of TTP. The addition of vincristine early in the course of the disease contributes to reduce autoantibodies and improves the response rates to PE. 9 In TA-TMA, in contrast, plasmapheresis induces a lower response rate, which may be partially attributed to the persistence of factors perpetuating endothelial injury. 3 In this subset of patients, vincristine alters the platelet membrane glycoprotein receptors, thus preventing their upregulation and binding to von Willebrand factor multimers. 9 In addition, its immunoregulatory effect also contributes to the control of underlying mechanisms that perpetuate the TA-TMA. 10 The results described in the current study, although in a low number of patients, show that vincristine is a secure and useful adjuvant to PE in severe TA-TMA, while in less severe cases it can be used as a single agent. Our study supports the development of further studies in a larger numbers of patients using vincristine earlier in the course of the disease. Table 1 Patients' characteristics and outcome 
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